Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Medulloblastoma - Overview
Medulloblastoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Medulloblastoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Medulloblastoma - Companies Involved in Therapeutics Development
Medulloblastoma - Drug Profiles
Medulloblastoma - Dormant Projects
Medulloblastoma - Discontinued Products
Medulloblastoma - Product Development Milestones
Featured News & Press Releases
Jun 21, 2022: Orphan Desigtion granted by EMA to MTX110 development for the treatment of Glioma
Jul 15, 2021: Abstract published in Neuro-Oncology demonstrates Curta Pharmaceuticals’ CT-179 prolonged event-free survival in an animal model of medulloblastoma
Dec 01, 2020: Moleculin announces FDA approves 3 rare pediatric disease desigtions for WP1066
Nov 11, 2020: ONC206 efficacy in brain tumors to be presented at 2020 SNO Conference
Aug 20, 2019: Moleculin announces CTRC approval of WP1066 pediatric brain tumor trial
Jun 11, 2018: Reviving the protector: new tactic against medulloblastoma
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Medulloblastoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Medulloblastoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Target, 2022 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Medulloblastoma - Dormant Projects, 2022
Medulloblastoma - Dormant Projects, 2022 (Contd..1)
Medulloblastoma - Discontinued Products, 2022